Abstract:What is known and objectiveThere are numerous studies on population pharmacokinetics of vancomycin in adult patients. However, there is no such research for Chinese adult patients. This study was conducted to evaluate the predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients and to identify some models appropriate for our population.MethodsA literature search was conducted in PubMed to obtain the population pharmacokinetic models of vancomycin published between December 2010 and September 2012. The models were assessed using concentration data collected from Chinese patients for external validation. Models with relatively poor predictability were excluded from further analysis. The performance of the remaining models was evaluated in patients with different levels of creatinine clearance, age, body weight and sex by Bayesian method. This method was also used to compare the predictive performance based on peak concentration and trough concentration and the predictability based on different number of observed concentrations.ResultsOne hundred and sixty-five blood concentrations from 72 Chinese adult patients were collected retrospectively to serve as the test data set. The evaluated models included all those reported in the seven publications reviewed by Marsot etal. and three other studies published after December 2010. Three models with poor performance on external validation were excluded from the next Bayesian analysis. The distribution of covariates in the model building data set had an important effect on prediction. The predictability based on peak/trough concentration was similar among the evaluated models, and no significant difference was found using our data set except for Roberts' model. As expected, an increased number of samples improved the performance of the Bayesian prediction.What is new and conclusionWith our data set, the performance of the evaluated models varied. The characteristics of the patient population and distribution of covariates should be given more consideration when choosing a model to predict blood concentrations. The model developed by Purwonugroho etal. using a data set from patients similar to ours is appropriate for Bayesian dose predictions for vancomycin concentrations in our population of Chinese adult patients.

Vancomycin in Neonatal Sepsis: Predictive Performance of a Chinese Neonatal Population Pharmacokinetic Model and Clinical Efficacy Evaluation

Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing

Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation

External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers

Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections.

Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model

Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

Population Pharmacokinetics Modeling of Vancomycin Among Chinese Infants With Normal and Augmented Renal Function

Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates

Population Pharmacokinetics Of Vancomycin In Chinese Pediatric Patients

External validation of vancomycin population pharmacokinetic models in ten cohorts of infected Chinese patients

Population Pharmacokinetics of Vancomycin in Chinese Infants

Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients

Predictive Performance of Reported Population Pharmacokinetic Models of Vancomycin in Chinese Adult Patients

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates

Population Pharmacokinetics of Vancomycin and Prediction of Pharmacodynamics in the Chinese People

Comparison of the predictive accuracy of the physiologically based pharmacokinetic (PBPK) model and population pharmacokinetic (PPK) model of vancomycin in Japanese patients with MRSA infection

Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens

Optimisation of Vancomycin Exposure in Neonates Based on the Best Level of Evidence.

External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: the Transferability of Published Models to Different Clinical Settings.